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A 42 year-old female presented with a right submandibular mass and was diagnosed 
with stage IVA grade II follicular lymphoma. After receiving multiple lines of treatment, 
(including CHOP, FMD, autologous transplant, rituximab and yttrium-90-ibritumomab) 
she underwent an unrelated, HLA-mismatched (9/10), non-myeloablative, allogeneic 
peripheral blood stem cell transplantation in partial remission December 29 th, 2006. 
Conditioning regimen consisted of fludarabine and melphalan [1]. Cyclosporin and 
mycophenolate-mofetil were used as graft-versus host disease (GVHD) prophylaxis. 
Patient and donor had EBV IgG antibodies. Complete chimerism was documented on 
day +28, remaining stable up to date. She developed grade II (skin III, gastrointestinal 
I) acute GVHD managed with metil-prednisolone (2mg/Kg) and beclometasone 
(2mg/6h). Signs and symptoms subsided on day +54 and steroids were tapered. 
On day +100, she presented with a right inguinal mass. PET/CT-scan showed right 
iliac (1.5x2.5cm) and inguinal (3x1.5cm) lymphadenopaties, the latter FDG avid 
(SUV10.5). Incisional biopsy of the right inguinal node showed DLBCL with a 
proliferation index of 90%; EBV was negative; qualitative PCR showed the presence of 
the BCL2/JH (Mbr) rearrangement; cytogenetics and FISH detected the t(14;18) with 
no other added lesions; GeneScanning analysis and sequencing of the immunoglobulin 
chain gene rearrangement VK-Kde was identical to that detected at diagnosis 
confirming the re-appearance of the malignant clone and thus the diagnosis of relapsed 
disease transformed to diffuse large B cell lymphoma (Fig.1a) [2]. Flow cytometric 
analysis on lymphadenopathy cell suspensions identified a B-cell malignancy 
intermingled with a polyclonal T-cell population representing 42% of the cellularity; 
chimerism analysis (STR&GeneScanning) detected 42% of donor cells and 58% of 
patient cells (fig.1b). Taken together, results can be explained by the presence in the 
sample of patient-derived clonal B-cells together with infiltrating T-cell lymphocytes 
(TIL-T) of donor origin, findings suggestive of an active graft versus lymphoma effect.  
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Baseline immunosuppression was reduced and she received 4 doses of single agent 
rituximab at a standard dose. Three months later, re-evaluation with PET/CT and bone 
marrow biopsy showed complete remission. She developed chronic GVHD affecting 
the gastrointestinal tract and joints (+874) and is currently taking tacrolimus and 
steroids at a low-dose. Repeated follow-up imaging, including the most recent PET/CT 
scan (February09) showed no significant abnormalities. There is no evidence of 
disease in the last bone marrow assessment (March09).  
In summary, our patient presented with a rapidly enlarging, PET positive, right inguinal 
node early post-allotransplant. A post-transplant lymphoproliferative disorder was 
suspected but an identical immunoglobulin chain gene rearrangement to that detected 
at diagnosis was identified, confirming the diagnosis of relapsed lymphoma 
transformed to DLBCL. The frequency of this entity is unknown since most studies do 
not specify/confirm histologies at relapse [3-6]. Despite the poor prognosis of 
transformed follicular lymphoma [7], our patient remains clinically and radiologically in 
complete remission on day +915 post-transplant. It is likely rituximab and a GVL effect 
exerted by a TIL-T population and forced by reducing the immunosuppression 
influenced the outcome of our patient [8,9].  
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FIGURE LEGENDS 
Figure 1a.  GeneScanning analysis of kappa light chain immunoglobulin rearrangement 
(VK -Kde) at diagnosis and at relapse post-allogeneic stem cell transplantation. Note 
that PCR product size is similar in both samples and therefore highly suggestive of 
relapsed disease.  
Figure1b. Chimerism analysis at relapse post-allogeneic transplantation showing 
recipient, donor and recipient´s adenopathy short tandem repeat (STR) genotypes. 
Focused on shadowed peaks in adenopathy sample, arrows point out peaks of 
recipient origin. 
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